PATENT CLAIM ANALYSIS

Application Number: 16038643
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-02
Patent Classification: ["424", "093210"]

Abstract:
The disclosed methods are generally directed to preventing, treating, suppressing, controlling or otherwise mitigating side effects of T-cell therapy, the T-cell therapy designed to accelerate immune reconstitution, induce a GVM effect, and/or target tumor cells.

Claim (Index 15):
The method of  claim 13 , wherein the positive selection comprises contacting the generated HPRT deficient lymphocytes with both a purine analog and allopurinol.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 95.0
- Lexical Diversity: 1.23529
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15155776', '14112878', '15625819', '13669194', '14296404']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6156742151792317
- 35 USC 102 Novelty (BERT): 0.5265931586751278
- Combined Prediction Score: 0.6067661095288214
- Mean Citation Score: 256.54293
- Max Citation Score: 280.3173
- Similarity Product: 171.36262472893594

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test